These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 18259029)

  • 1. Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study.
    Os I; Franco V; Kjeldsen SE; Manhem K; Devereux RB; Gerdts E; Hille DA; Lyle PA; Okin PM; Dahlöf B; Oparil S
    Hypertension; 2008 Apr; 51(4):1103-8. PubMed ID: 18259029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
    Wachtell K; Hornestam B; Lehto M; Slotwiner DJ; Gerdts E; Olsen MH; Aurup P; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Rokkedal J; Devereux RB
    J Am Coll Cardiol; 2005 Mar; 45(5):705-11. PubMed ID: 15734614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
    Wachtell K; Lehto M; Gerdts E; Olsen MH; Hornestam B; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Devereux RB
    J Am Coll Cardiol; 2005 Mar; 45(5):712-9. PubMed ID: 15734615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gender differences in left ventricular structure and function during antihypertensive treatment: the Losartan Intervention for Endpoint Reduction in Hypertension Study.
    Gerdts E; Okin PM; de Simone G; Cramariuc D; Wachtell K; Boman K; Devereux RB
    Hypertension; 2008 Apr; 51(4):1109-14. PubMed ID: 18259011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.
    Fyhrquist F; Dahlöf B; Devereux RB; Kjeldsen SE; Julius S; Beevers G; de Faire U; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Hille DA; Lyle PA; Edelman JM; Snapinn SM; Wedel H;
    Hypertension; 2005 Apr; 45(4):580-5. PubMed ID: 15790960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients.
    Okin PM
    J Electrocardiol; 2009; 42(6):584-8. PubMed ID: 19631946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study.
    Fossum E; Gleim GW; Kjeldsen SE; Kizer JR; Julius S; Devereux RB; Brady WE; Hille DA; Lyle PA; Dahlöf B
    J Intern Med; 2007 Oct; 262(4):439-48. PubMed ID: 17875180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy.
    Franklin SS; Wachtell K; Papademetriou V; Olsen MH; Devereux RB; Fyhrquist F; Ibsen H; Kjeldsen SE; Dahlöf B
    Hypertension; 2005 Sep; 46(3):492-9. PubMed ID: 16116047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).
    Okin PM; Oikarinen L; Viitasalo M; Toivonen L; Kjeldsen SE; Nieminen MS; Edelman JM; Dahlöf B; Devereux RB;
    Circulation; 2009 Apr; 119(14):1883-91. PubMed ID: 19332468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: the LIFE study.
    Larstorp AC; Okin PM; Devereux RB; Olsen MH; Ibsen H; Dahlöf B; Kjeldsen SE; Wachtell K
    J Hum Hypertens; 2011 Mar; 25(3):178-85. PubMed ID: 20505749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study.
    Olsen MH; Wachtell K; Beevers G; Dahlöf B; Devereux RB; de Faire U; Fyhrquist F; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Narayan P; Nieminen MS; Omvik P; Oparil S; Wedel H
    Am Heart J; 2009 Jan; 157(1):177-84. PubMed ID: 19081416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
    Kjeldsen SE; Dahlöf B; Devereux RB; Julius S; Aurup P; Edelman J; Beevers G; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Snapinn S; Wedel H;
    JAMA; 2002 Sep; 288(12):1491-8. PubMed ID: 12243636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study.
    Olsen MH; Wachtell K; Beevers G; Dahlöf B; de Simone G; Devereux RB; de Faire U; Fyhrquist F; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Lyle PA; Nieminen MS; Omvik P; Oparil S; Wedel H
    J Hypertens; 2009 Mar; 27(3):567-74. PubMed ID: 19262226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study].
    Ibsen H; Pedersen OL; Dahlöf B; Kjeldsen SE; Lindholm LH
    Ugeskr Laeger; 2003 Jan; 165(5):456-9. PubMed ID: 12599843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study.
    Reims HM; Kjeldsen SE; Brady WE; Dahlöf B; Devereux RB; Julius S; Beevers G; De Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
    J Hum Hypertens; 2004 Jun; 18(6):381-9. PubMed ID: 15103313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.
    Ibsen H; Wachtell K; Olsen MH; Borch-Johnsen K; Lindholm LH; Mogensen CE; Dahlöf B; Devereux RB; de Faire U; Fyhrquist F; Julius S; Kjeldsen SE; Lederballe-Pedersen O; Nieminen MS; Omvik P; Oparil S; Wan Y;
    J Hypertens; 2004 Sep; 22(9):1805-11. PubMed ID: 15311110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of hypertension in patients with left ventricular hypertrophy].
    Omvik P; Bratland B; Gerhardsen G; Gisholt K; Risanger T; Smedsrud T; Kjeldsen SE
    Tidsskr Nor Laegeforen; 2004 Mar; 124(6):788-91. PubMed ID: 15039810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of serum uric acid on cardiovascular outcomes in the LIFE study.
    Høieggen A; Alderman MH; Kjeldsen SE; Julius S; Devereux RB; De Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Chen C; Dahlöf B;
    Kidney Int; 2004 Mar; 65(3):1041-9. PubMed ID: 14871425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study.
    Li Z; Dahlöf B; Okin PM; Kjeldsen SE; Wachtell K; Ibsen H; Nieminen MS; Jern S; Devereux RB
    J Hypertens; 2008 Jun; 26(6):1244-9. PubMed ID: 18475164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher pulse pressure/stroke volume index is associated with impaired outcome in hypertensive patients with left ventricular hypertrophy the LIFE study.
    Mancusi C; Gerdts E; de Simone G; Midtbø H; Lønnebakken MT; Boman K; Wachtell K; Dahlöf B; Devereux RB
    Blood Press; 2017 Jun; 26(3):150-155. PubMed ID: 27710139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.